The biotech is developing a Huntington’s disease (HD) gene therapy based on its proprietary capsid, AAV-DB-3. HD damages the neurons in the striatum, leading Latus to target the deep brain.

Capsida Biotherapeutics has unveiled data showing that its AAV-delivered gene therapy for ... in epilepsy med The therapy restored syntaxin-binding protein 1 (STXBP1) protein levels in 70% of ...